IDXX · XBRL financial data

Idexx Laboratories financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (IDXX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	902*	964	1,004	976	954*	998	1,109	1,105	1,091*	1,141	1,217	1,214
Cost of revenue	375*	371	384	380	—	375	—	—	—	—	—	—
Cost of goods and services sold	year only	—	384	380	384*	375	415	422	432*	418	437	450
Gross profit	526*	593	619	596	571*	623	695	683	658*	723	779	764
Research and development	52*	53	55	54	58*	59	62	63	67*	66	65	69
General and administrative	87*	92	157	92	101*	92	99	106	109*	119	117	123
Total operating expenses	year only	294	355	292	309*	307	322	329	343*	360	354	362
Operating income (loss)	245*	299	264	304	262*	317	373	355	316*	363	426	402
Interest expense	9*	8	8	8	7*	8	11	11	9*	8	10	7
Income tax expense (benefit)	45*	60	56	66	40*	67	68	70	59*	77	79	82
Net income (loss)	195*	236	203	233	216*	243	294	275	248*	278	338	317
Earnings per share, basic USD per share	2.34*	2.84	2.46	2.83	2.64*	2.98	3.66	3.43	3.11*	3.50	4.29	4.02
Earnings per share, diluted USD per share	2.32*	2.81	2.44	2.80	2.62*	2.96	3.63	3.40	3.08*	3.47	4.27	4.01
Weighted average shares, basic millions of shares	83*	83	83	82	82*	81	80	80	80*	80	79	79
Weighted average shares, diluted millions of shares	84*	84	83	83	83*	82	81	81	81*	80	79	79

Fiscal quarters (IDXX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	454	397	402	309	288	164	165	208	180	201	197	198
Accounts receivable	457	507	534	511	474	527	561	567	552	604	627	616
Inventory	380	391	380	390	382	396	393	392	378	382	392	391
Total current assets	1,495	1,502	1,529	1,434	1,400	1,318	1,362	1,477	1,414	1,454	1,509	1,500
Property and equipment, net	702	709	708	718	713	718	740	739	747	740	733	732
Right-of-use asset	115	120	120	121	116	116	130	128	123	121	123	120
Goodwill	366	409	408	412	405	407	414	414	414	412	411	641
Total assets	3,260	3,354	3,415	3,351	3,293	3,214	3,331	3,387	3,351	3,385	3,442	3,707
Accounts payable	111	117	117	111	114	120	117	122	110	130	129	154
Accrued liabilities	479	476	541	511	502	491	417	489	530	454	453	521
Current portion of long-term debt	75	75	170	99	168	171	75	150	75	150	150	75
Total current liabilities	952	957	1,117	1,009	1,068	1,136	1,224	1,252	1,149	1,300	1,288	1,264
Long-term debt	623	621	525	525	450	450	450	375	375	300	300	300
Lease liability, non-current	100	104	103	103	98	97	108	106	101	99	101	98
Total liabilities	1,775	1,785	1,835	1,733	1,698	1,766	1,872	1,826	1,745	1,829	1,830	1,838
Retained earnings	4,445	4,680	4,883	5,116	5,332	5,575	5,869	6,144	6,392	6,670	7,009	7,326
Total stockholders' equity	1,485	1,569	1,580	1,618	1,595	1,448	1,459	1,561	1,605	1,556	1,613	1,869
Total liabilities and equity	3,260	3,354	3,415	3,351	3,293	3,214	3,331	3,387	3,351	3,385	3,442	3,707
Common shares outstanding (cover page) millions of shares	83	83	82	82	81	80	80	80	80	79	79	79

Fiscal quarters (IDXX's year ends in late December)

In millions of dollars	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	195*	236	203	233	216*	243	294	275	248*	278	338	317
Stock-based compensation	15*	14	16*	16*	14*	15	15*	14*	16*	16	16*	16*
Depreciation and amortization	30*	30	32*	34*	34*	34	36*	37*	39*	38	41*	41*
Net cash from operating activities	250*	199	248*	220*	262*	238	186*	402*	356*	266	347*	450*
Purchases of property and equipment	33*	30	33*	28*	29*	30	34*	31*	29*	32	25*	29*
Net cash from investing activities	(30)*	(107)	(33)*	(27)*	(40)*	(30)	(34)*	(45)*	(28)*	(34)	(25)*	(248)*
Share repurchases	37*	155	216*	221*	246*	401	338*	240*	238*	351	347*	112*
Net cash from financing activities	(102)*	(144)	(210)*	(291)*	(233)*	(330)	(166)*	(313)*	(356)*	(211)	(325)*	(201)*
Net change in cash	122*	(56)	4*	(93)*	(20)*	(124)	1*	44*	(28)*	20	(4)*	1*

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Quarter
Idexx Laboratories	198	1,214	450*	78.8M	Q3 FY26 10-QSep 30, 2026
Alnylam Pharmaceuticals	1,754	1,458	341*	133.9M	Q3 FY26 10-QSep 30, 2026
Regeneron Pharmaceuticals	3,659	5,116	1,783*	not reported	Q3 FY26 10-QSep 30, 2026
Zoetis	1,476	2,468	655*	413.2M	Q2 FY26 10-QJun 30, 2026
INSMED	397	524	(36)*	219.4M	Q3 FY26 10-QSep 30, 2026
Bristol Myers Squibb	9,574	13,069	4,181*	2.0B	Q3 FY26 10-QSep 30, 2026
Biogen	1,304	2,804	641*	147.8M	Q3 FY26 10-QSep 30, 2026
Teva Pharmaceutical Industries	4,085	4,395	241	1.2B	Q3 FY26 10-QSep 30, 2026
Gilead Sciences	6,437	8,300	5,035*	1.2B	Q3 FY26 10-QSep 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.